VIP (10mg vials)
Price range: $150.00 through $990.00
For Research Use Only. Not for Use in diagnostic procedures.
This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.
đ„ Exclusive Crypto Offer
Get an INSTANT 15% DISCOUNT when you pay with Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, XRP, Solana, or USDT.
⥠Don't have crypto? Buy it here in 5 minutes with easy guidance.
đĄ Pro Tip: You can also pay with cryptocurrency using your verified Cash App or PayPal account for a fast and secure checkout!
VIP
Vasoactive Intestinal Peptide
Independently Certified USP<85> Endotoxin Safe
Save over 60%!
Swipe right to view full table â
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
20mg, 50mg, 100mg, 200mg |
Cost per milligram |
$4.95 â $7.50 |
Multi-vial Purity |
99.42% |
Endotoxin Screening |
PASSED |
Purity Screening |
PASSED |
Independently Tested |
YES |
Peptide Partners Manufacturer Id: SH07
Batch Id: VP20250511
Research Studies
(for educational purposes only)
Study 1: Vasoactive Intestinal Peptide (VIP) in COVID-19 TherapyâShedding of ACE2 and TMPRSS2 via ADAM10
Authors: Charlotte Gutzler, Kerstin Höhne, Daniele Bani, Gian Kayser, Sebastian FĂ€hndrich, Michael Ambros, Martin J Hug, Siegbert Rieg, Valeria Falcone, Joachim MĂŒller-Quernheim, Gernot Zissel, Björn C Frye
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11942504/
Scientific Findings
This in vitro study investigated the effect of Vasoactive Intestinal Peptide (VIP) on the expression of SARS-CoV-2 entry receptors, ACE2 and TMPRSS2, in cell cultures. The results demonstrate that VIP downregulates the transcription of both ACE2 and TMPRSS2 genes, leading to reduced protein expression on the cell surface. Furthermore, VIP was shown to induce the shedding of these receptors from the cell surface, a process mediated by the metalloprotease ADAM10. This was confirmed by the observation that the ADAM10 inhibitor, Aderbasib, blocked the VIP-induced shedding. The functional consequence of these changes was a reduction in the proteolytic activity of TMPRSS2 and a decreased infection rate of cells by a SARS-CoV-2 pseudovirus. These findings suggest that VIP may inhibit SARS-CoV-2 cellular entry by a dual mechanism: reducing the expression and promoting the shedding of its entry receptors.
Plain English Interpretation
Scientists investigated how a natural peptide in our bodies, called VIP, might help fight off the virus that causes COVID-19. In laboratory experiments using cells, they discovered that VIP can make it harder for the virus to get into cells. It does this in two ways: first, it tells the cells to make less of the âdoorknobsâ (receptors called ACE2 and TMPRSS2) that the virus uses to enter. Second, it helps to âcut offâ the doorknobs that are already on the cell surface, so the virus has nothing to grab onto. This one-two punch effectively reduces the number of entry points for the virus, making it more difficult for the cells to become infected. These findings suggest that VIP could be a potential therapeutic agent for COVID-19 by blocking the virus from entering our cells in the first place.
Study 2: Vasoactive intestinal peptide produces long-lasting changes in neural activity in the suprachiasmatic nucleus
Authors: Takashi Kudo, Yu Tahara, Karen L Gamble, Douglas G McMahon, Gene D Block, Christopher S Colwell
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4073931/
Scientific Findings
This study investigated the long-term effects of vasoactive intestinal peptide (VIP) on the electrical activity of neurons in the suprachiasmatic nucleus (SCN) using mouse brain slice cultures. Application of VIP induced a sustained increase in neuronal firing rate that persisted for several hours. This effect was mediated by the VIP receptor VIPR2, as it was blocked by a VIP receptor antagonist and absent in VIPR2 knockout mice. The downstream signaling pathway involves the activation of both PKA and Epac, leading to an increase in cAMP. The study also demonstrated that the persistent increase in firing rate was dependent on the clock protein PER1 and the Kv3 potassium channels, suggesting that VIP regulates the fast delayed rectifier (FDR) potassium currents to produce long-lasting changes in SCN neuronal excitability.
Plain English Interpretation
Our internal body clock, located in a brain region called the SCN, controls our daily rhythms. A molecule called VIP is known to be important for the function of this clock, but how it works was not fully understood. In this study, researchers used slices of mouse brain tissue kept alive in a dish to study the effects of VIP on the brain cells of the SCN. They found that VIP caused a long-lasting increase in the electrical activity of these cells, making them fire more frequently for several hours. This effect was triggered by VIP binding to a specific receptor on the cell surface, which in turn activated a chain of chemical reactions inside the cell. The study also revealed that this process depends on a specific âclock geneâ and certain channels that control the flow of potassium in and out of the cells. These findings suggest that VIP plays a crucial role in regulating the long-term activity of our internal clock, which could have implications for understanding and treating sleep disorders and other conditions related to circadian rhythms.
Study 3: Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury
Authors: Tatiana Agibalova, Anneke Hempel, H Carlo Maurer, Mohab Ragab, Anastasia Ermolova, Jessica Wieland, Caroline Waldherr Ăvila de Melo, Fabian Heindl, Maximilian Giller, Julius Clemens Fischer, Markus Tschurtschenthaler, Birgit Kohnke-Ertel, Rupert Ăllinger, Katja Steiger, Ihsan Ekin Demir, Dieter Saur, Michael Quante, Roland M Schmid, Moritz Middelhoff
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11462795/
Scientific Findings
This study demonstrates that Vasoactive Intestinal Peptide (VIP) promotes the differentiation of intestinal epithelial cells towards a secretory phenotype, a process mediated by the p38 MAPK pathway. In vitro experiments using intestinal organoids revealed that VIP modulates the proliferation of Lgr5-EGFP+ progenitor cells under homeostatic conditions. Furthermore, in a model of radiation-induced intestinal injury, VIP was shown to enhance epithelial regeneration. The study found that irradiated Lgr5-EGFP+ progenitor cells were more susceptible to VIP-induced modulation, which promoted their regenerative capacity. These findings suggest that VIP plays a crucial role in maintaining intestinal homeostasis and mitigating radiation-induced damage by promoting secretory differentiation and epithelial regeneration.
Plain English Interpretation
Scientists studied how the peptide VIP affects intestinal cells grown in a lab. They found that VIP encourages these cells to become specialized âsecretoryâ cells, which are important for a healthy gut lining. They also discovered that VIP helps the gutâs stem cells to grow and multiply. When the intestinal cells were damaged by radiation, VIP helped them to heal and regenerate more effectively. This suggests that VIP could be a potential treatment to protect the intestines from damage caused by radiation therapy.
VIP
Vasoactive Intestinal Peptide
Independently Certified USP<85> Endotoxin Safe
Save over 60%!
Swipe right to view full table â
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
20mg, 50mg, 100mg, 200mg |
Cost per milligram |
$4.95 â $7.50 |
Multi-vial Purity |
99.42% |
Endotoxin Screening |
PASSED |
Purity Screening |
PASSED |
Independently Tested |
YES |
Peptide Partners Manufacturer Id: SH07
Batch Id: VP20250511
Research Studies
(for educational purposes only)
Study 1: Vasoactive Intestinal Peptide (VIP) in COVID-19 TherapyâShedding of ACE2 and TMPRSS2 via ADAM10
Authors: Charlotte Gutzler, Kerstin Höhne, Daniele Bani, Gian Kayser, Sebastian FĂ€hndrich, Michael Ambros, Martin J Hug, Siegbert Rieg, Valeria Falcone, Joachim MĂŒller-Quernheim, Gernot Zissel, Björn C Frye
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11942504/
Scientific Findings
This in vitro study investigated the effect of Vasoactive Intestinal Peptide (VIP) on the expression of SARS-CoV-2 entry receptors, ACE2 and TMPRSS2, in cell cultures. The results demonstrate that VIP downregulates the transcription of both ACE2 and TMPRSS2 genes, leading to reduced protein expression on the cell surface. Furthermore, VIP was shown to induce the shedding of these receptors from the cell surface, a process mediated by the metalloprotease ADAM10. This was confirmed by the observation that the ADAM10 inhibitor, Aderbasib, blocked the VIP-induced shedding. The functional consequence of these changes was a reduction in the proteolytic activity of TMPRSS2 and a decreased infection rate of cells by a SARS-CoV-2 pseudovirus. These findings suggest that VIP may inhibit SARS-CoV-2 cellular entry by a dual mechanism: reducing the expression and promoting the shedding of its entry receptors.
Plain English Interpretation
Scientists investigated how a natural peptide in our bodies, called VIP, might help fight off the virus that causes COVID-19. In laboratory experiments using cells, they discovered that VIP can make it harder for the virus to get into cells. It does this in two ways: first, it tells the cells to make less of the âdoorknobsâ (receptors called ACE2 and TMPRSS2) that the virus uses to enter. Second, it helps to âcut offâ the doorknobs that are already on the cell surface, so the virus has nothing to grab onto. This one-two punch effectively reduces the number of entry points for the virus, making it more difficult for the cells to become infected. These findings suggest that VIP could be a potential therapeutic agent for COVID-19 by blocking the virus from entering our cells in the first place.
Study 2: Vasoactive intestinal peptide produces long-lasting changes in neural activity in the suprachiasmatic nucleus
Authors: Takashi Kudo, Yu Tahara, Karen L Gamble, Douglas G McMahon, Gene D Block, Christopher S Colwell
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4073931/
Scientific Findings
This study investigated the long-term effects of vasoactive intestinal peptide (VIP) on the electrical activity of neurons in the suprachiasmatic nucleus (SCN) using mouse brain slice cultures. Application of VIP induced a sustained increase in neuronal firing rate that persisted for several hours. This effect was mediated by the VIP receptor VIPR2, as it was blocked by a VIP receptor antagonist and absent in VIPR2 knockout mice. The downstream signaling pathway involves the activation of both PKA and Epac, leading to an increase in cAMP. The study also demonstrated that the persistent increase in firing rate was dependent on the clock protein PER1 and the Kv3 potassium channels, suggesting that VIP regulates the fast delayed rectifier (FDR) potassium currents to produce long-lasting changes in SCN neuronal excitability.
Plain English Interpretation
Our internal body clock, located in a brain region called the SCN, controls our daily rhythms. A molecule called VIP is known to be important for the function of this clock, but how it works was not fully understood. In this study, researchers used slices of mouse brain tissue kept alive in a dish to study the effects of VIP on the brain cells of the SCN. They found that VIP caused a long-lasting increase in the electrical activity of these cells, making them fire more frequently for several hours. This effect was triggered by VIP binding to a specific receptor on the cell surface, which in turn activated a chain of chemical reactions inside the cell. The study also revealed that this process depends on a specific âclock geneâ and certain channels that control the flow of potassium in and out of the cells. These findings suggest that VIP plays a crucial role in regulating the long-term activity of our internal clock, which could have implications for understanding and treating sleep disorders and other conditions related to circadian rhythms.
Study 3: Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury
Authors: Tatiana Agibalova, Anneke Hempel, H Carlo Maurer, Mohab Ragab, Anastasia Ermolova, Jessica Wieland, Caroline Waldherr Ăvila de Melo, Fabian Heindl, Maximilian Giller, Julius Clemens Fischer, Markus Tschurtschenthaler, Birgit Kohnke-Ertel, Rupert Ăllinger, Katja Steiger, Ihsan Ekin Demir, Dieter Saur, Michael Quante, Roland M Schmid, Moritz Middelhoff
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11462795/
Scientific Findings
This study demonstrates that Vasoactive Intestinal Peptide (VIP) promotes the differentiation of intestinal epithelial cells towards a secretory phenotype, a process mediated by the p38 MAPK pathway. In vitro experiments using intestinal organoids revealed that VIP modulates the proliferation of Lgr5-EGFP+ progenitor cells under homeostatic conditions. Furthermore, in a model of radiation-induced intestinal injury, VIP was shown to enhance epithelial regeneration. The study found that irradiated Lgr5-EGFP+ progenitor cells were more susceptible to VIP-induced modulation, which promoted their regenerative capacity. These findings suggest that VIP plays a crucial role in maintaining intestinal homeostasis and mitigating radiation-induced damage by promoting secretory differentiation and epithelial regeneration.
Plain English Interpretation
Scientists studied how the peptide VIP affects intestinal cells grown in a lab. They found that VIP encourages these cells to become specialized âsecretoryâ cells, which are important for a healthy gut lining. They also discovered that VIP helps the gutâs stem cells to grow and multiply. When the intestinal cells were damaged by radiation, VIP helped them to heal and regenerate more effectively. This suggests that VIP could be a potential treatment to protect the intestines from damage caused by radiation therapy.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesnât submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratoryâs website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
Swipe right to view full table â
| Peptide | Batch Id | Manufacturer | Date | Purity | Laboratory | Double Validated | |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-02 | 99.71% | Kovera | View File | |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | 99.9% | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-07-02 | 99.77% | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-25 | 99.74% | Kovera | View File | |
| Tesamorelin | TES202607 | WF03 | 2026-06-19 | 99.80% | TrustPointe | View File | |
| KPV | KV202606 | WF03 | 2026-06-12 | 99.36% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-12 | 99.82% | TrustPointe | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-12 | 99.98% | TrustPointe | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-12 | 99.96% | TrustPointe | Yes | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | 99.36% | Kovera | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-10 | 99.88% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | 99.74% | Kovera | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | 99.71% | Kovera | Yes | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | 99.76% | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | 99.55% | Kovera | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | 99.68% | Kovera | Yes | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | 99.70% | Kovera | Yes | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | 99.34% | TrustPointe | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | 99.65% | Kovera | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | 99.90% | Kovera | Yes | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | 99.55% | TrustPointe | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-13 | 99.67% | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-13 | 99.86% | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | 99.78% | Kovera | Yes | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-29 | 99.53% | Chromate | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | 99.22% | TrustPointe | Yes | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-08 | 99.98% | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-08 | 99.94% | TrustPointe | Yes | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | 99.76% | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | 99.81% | TrustPointe | View File | |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | 99.75% | TrustPointe | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | 99.90% | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | 99.93% | TrustPointe | View File | |
| Cagrilintide | CG202607 | WF03 | 2026-05-14 | 99.74% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-05-14 | 99.73% | TrustPointe | Yes | View File |
| GHK-Cu | CU202604 | WF03 | 2026-05-14 | 99.74% | TrustPointe | Yes | View File |
| BPC-157 | BC202604 | VI32 | 2026-05-13 | 99.72% | TrustPointe | Yes | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | 99.82% | Kovera | View File | |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | 99.85% | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | 99.81% | Kovera | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | 99.90% | Kovera | Yes | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | 99.86% | Kovera | View File | |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | 99.93% | Kovera | View File | |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | 99.90% | Kovera | View File | |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | 99.96% | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | 99.54% | TrustPointe | View File | |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | 99.94% | Kovera | View File | |
| Pinealon | PN202603 | WF03 | 2026-04-01 | 99.96% | Kovera | View File | |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | 99.93% | Kovera | Yes | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | 99.82% | TrustPointe | View File | |
| Semax | SX202603 | WF03 | 2026-03-31 | 99.91% | Kovera | View File | |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | 99.40% | TrustPointe | View File | |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | 99.88% | Kovera | View File | |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | 99.89% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-27 | 99.63% | TrustPointe | View File | |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | 99.52% | TrustPointe | View File | |
| BPC-157 | BC202604 | VI32 | 2026-03-18 | 99.60% | TrustPointe | Yes | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202602 | WF03 | 2026-02-27 | 99.92% | TrustPointe | View File | |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | 99.95% | Kovera | View File | |
| KLOW | KW202602 | WF03 | 2026-03-01 | 99.86% | Chromate | View File | |
| NAD+ | NDB202601 | VI32 | 2026-02-07 | 99.92% | Kovera | View File | |
| SS-31 | SS202602 | WF03 | 2026-02-08 | 99.68% | Chromate | View File | |
| MOTS-c | MC202602 | WF03 | 2026-02-09 | 99.41% | Chromate | View File | |
| Selank | SEK202601 | VI32 | 2026-01-29 | 99.94% | Chromate | View File | |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-20 | 99.85% | Chromate | View File | |
| KPV | KV202601 | VI32 | 2026-01-20 | 99.90% | Chromate | View File | |
| Ipamorelin | IP202601 | WF03 | 2026-01-14 | 99.92% | TrustPointe | View File | |
| TB500 (TB4) | TB202601 | WF03 | 2026-01-14 | 99.86% | TrustPointe | View File | |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | 99.63% | TrustPointe | View File | |
| PT-141 | PT202512 | VI32 | 2026-01-12 | 99.89% | BioRegen | View File | |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | 99.70% | TrustPointe | View File | |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | 99.33% | TrustPointe | View File | |
| Tesamorelin | TES202601 | WF03 | 2025-12-29 | 99.71% | TrustPointe | View File | |
| BPC-157 | BP202512 | WF03 | 2025-12-29 | 99.46% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-29 | 99.64% | TrustPointe | View File | |
| GHK-Cu | GK202512 | SH07 | 2025-12-19 | 99.79% | BioRegen | View File | |
| MOTS-c | MC202512 | WF03 | 2025-12-22 | 99.89% | BioRegen | View File | |
| Retatrutide | RP260130 | VI32 | 2025-12-22 | 99.72% | TrustPointe | View File | |
| SS-31 | SS202512 | WF03 | 2025-12-19 | 99.70% | TrustPointe | View File | |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | 99.63% | TrustPointe | View File | |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-09 | 99.80% | TrustPointe | View File | |
| Retatrutide | RP202511 | DF05 | 2025-12-19 | 99.73% | TrustPointe | View File | |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | 99.33% | TrustPointe | View File | |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | 99.86% | TrustPointe | View File | |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | 99.74% | TrustPointe | View File | |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | 99.47% | TrustPointe | View File | |
| Humanin | HP20250805 | WF03 | 2025-09-19 | 99.92% | BioRegen | View File | |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | 99.87% | BioRegen | View File | |
| DSIP | DS20250820 | SH07 | 2025-09-19 | 99.88% | BioRegen | View File | |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | 99.70% | BioRegen | View File | |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-11 | 99.84% | TrustPointe | View File | |
| BPC-157 | BP20250808 | WF03 | 2025-09-05 | 99.99% | TrustPointe | View File | |
| Sermorelin | SM20250723 | WF03 | 2025-08-27 | 99.84% | BioRegen | View File | |
| Tesamorelin | TS20250722 | WF03 | 2025-08-22 | 99.10% | TrustPointe | View File | |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | 99.43% | TrustPointe | View File | |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | 99.34% | TrustPointe | View File | |
| Ipamorelin | IP20250721 | WF03 | 2025-08-15 | 99.64% | TrustPointe | View File | |
| GHK-Cu | CU20250717 | SH07 | 2025-08-09 | 99.73% | BioRegen | View File | |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-08 | 99.41% | TrustPointe | View File | |
| NAD+ | ND20250503 | SH07 | 2025-07-31 | 99.76% | BioRegen | View File | |
| VIP | VP20250511 | SH07 | 2025-07-31 | 99.42% | BioRegen | View File | |
| Retatrutide | CD20250708 | SH07 | 2025-07-25 | 99.42% | TrustPointe | View File | |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | 99.52% | TrustPointe | View File | |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | 99.68% | TrustPointe | View File |
Current Endotoxin Certifications
Swipe right to view full table â
| Peptide | Batch Id | Manufacturer | Date | USP Conformation | Laboratory | |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Conforms | Kovera | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-22 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-15 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-11 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | Conforms | TrustPointe | View File |
| Epithalon | ET202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| DSIP | DS202605 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | Conforms | TrustPointe | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | Conforms | Kovera | View File |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202601 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-02-08 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-28 | Conforms | TrustPointe | View File |
| KPV | KV202601 | VI32 | 2026-01-28 | Conforms | TrustPointe | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| PT-141 | PT202512 | VI32 | 2026-01-07 | Conforms | BioRegen | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-06 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| Retatrutide | RP260130 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| SS-31 | SS202512 | WF03 | 2025-12-19 | Conforms | TrustPointe | View File |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-08 | Conforms | TrustPointe | View File |
| Retatrutide | RP202511 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | Conforms | TrustPointe | View File |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | Conforms | TrustPointe | View File |
| Humanin | HP20250805 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| DSIP | DS20250820 | SH07 | 2025-09-19 | Conforms | BioRegen | View File |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-08-27 | Conforms | BioRegen | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-08-11 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-08-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-04 | Conforms | TrustPointe | View File |
| NAD+ | ND20250503 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| VIP | VP20250511 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| Retatrutide | CD20250708 | SH07 | 2025-07-24 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
Current Heavy Metal Certifications
Swipe right to view full table â
| Peptide | Batch Id | Manufacturer | Date | Class 1 USP | Full USP | Laboratory |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-01 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-07-01 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| KPV | KV202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-25 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-13 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-11 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| TB-500 | TB202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| AOD-9604 | AO202605 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| KLOW Blend | KW202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-04-26 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| MOTS-c | MC202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-05-05 | Conforms | TrustPointe | View File |
| SS-31 | SS202601 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| DSIP | DS202605 | WF03 | 2026-04-24 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-02 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-03-31 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| SS-31 | SS202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Tesamorelin | TES202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Sermorelin | SER202601 | VI32 | 2026-03-29 | Conforms | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-26 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-26 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-19 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-12-03 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-24 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-12 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| SS-31 | SY20250806 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-11-12 | Conforms | TrustPointe | View File |
Current Sterility Certifications
Swipe right to view full table â
| Product | Batch Id | Manufacturer | Date | USP Pass/Fail | Rapid Pass/Fail | Laboratory | File |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Pass | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-26 | Pass | TrustPointe | View File | |
| MOTS-c | MC202605 | WF03 | 2026-06-23 | Pass | TrustPointe | View File | |
| NAD+ | NDB202606 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Pass | Kovera | View File | |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Pass | Kovera | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| KPV | KV202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| Retatrutide | RT202605 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-29 | Pass | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Cagrilintide | CG202607 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Pass | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | Pass | – | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Pass | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Pass | – | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | – | Pass | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | – | Pass | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-12 | Pass | – | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-12 | – | Pass | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Pass | – | Kovera | View File |
| Bacteriostatic Water | BAC202601 | WF03 | 2026-01-13 | Pass | – | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-09-09 | Pass | – | TrustPointe | View File |
| Meta-Z | MZR20250713 | DF05 | 2025-08-26 | Pass | – | TrustPointe | View File |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratoryâs website shows that the certificate belongs to the supplier and the values havenât been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratoryâs website shows that the certificate belongs to the supplier and the values havenât been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isnât an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result: <x.xx EU/mL
Because itâs reported as â<x.xxâ this indicates the test did not detect endotoxin above the detection limit of the cartridge. - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the â<â).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and weâll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50â200% per USP <85>
NOT SUITABLE FOR HUMAN CONSUMPTION â INTENDED FOR RESEARCH ONLY
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.
Related products
Vasoactive